# Ipamorelin Dosage in Research: The Doses Studied, by Species and Route > Ipamorelin dosage as it appears in the research only — the doses studied in humans and animals, by route, plus its ~2-hour half-life. No human dosing guidance; third-person study data. Research-context doses only. This page records what investigators administered in published work; it is not a protocol and not advice. ## Read this first This page lists the doses that appear in published ipamorelin research — and only that. It does not tell anyone what to take, because there is no approved human dose: ipamorelin is not a medicine, and its one human efficacy trial failed [3]. Think of this as a record of what scientists put into rats, ferrets, and a handful of human volunteers, written down with the species and the route so the numbers mean something. Where you see a dose, it belongs to a study — never to you. The popular CJC-1295 'stack' protocols traded in online communities have no peer-reviewed human dosing basis at all and are described here as anecdote, not recommendation [3]. Half-life, the routes researchers have used, and how the material is handled in the lab all live below, in third person, the way the literature reports them. ## The doses studied, by species and route Across the published record, the doses cluster by what each study was testing: - **Human pharmacokinetics:** 4.21 to 140.45 nmol/kg intravenously over 15 minutes, as single doses, in eight healthy men [2]. - **Human Phase 2 ileus trial:** 0.03 mg/kg intravenously twice daily for up to 7 days, in 114 surgery patients [3]. - **Rat bone-growth study:** 18, 90, and 450 micrograms per day subcutaneously, divided three times daily, for 15 days [4]. - **Rat chronic-dosing study:** a 21-day subcutaneous course used to probe tolerance [7]. - **Rat GH-under-steroid study:** 0.4 to 1.6 mg/kg per day intravenously, four times daily [8]. - **Ferret cachexia study (2024):** 1 to 3 mg/kg intraperitoneally [5]. Notice the spread: nanomoles-per-kilogram in careful human pharmacology, milligrams-per-kilogram in rodents, and entirely different routes. These are not interchangeable, and none translate to a human protocol [3]. ## Half-life and the shape of the GH pulse Ipamorelin is short-acting. In the human pharmacokinetic study, the terminal half-life was about 2 hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The GH response it triggers is not a long plateau but a single discrete pulse, peaking roughly 40 minutes (0.67 hours) after dosing [2]. In rats, plasma clearance was reported to be roughly 5-fold lower than for GHRP-6 [2]. The practical research implication is simple: the molecule comes and goes quickly, and the GH effect it produces is a brief spike rather than a sustained elevation [2]. ## Routes researchers have used Published ipamorelin work spans several routes, each tied to a purpose. Intravenous dosing carried the human pharmacokinetic and clinical-trial work and much rodent efficacy testing [2][3]. Subcutaneous dosing dominates the rodent bone and body-composition studies — and is also the route most community research use relies on, though without published human characterization [4]. Intranasal and intraperitoneal routes appear in rodent and ferret work [5]. Plain ipamorelin is not orally bioavailable; only engineered ipamorelin-derived analogs have shown meaningful oral absorption in animals [4]. The route always matters: a dose means nothing without the way it was delivered [2]. ## How much cjc-1295 ipamorelin should i take There is no research-validated answer to 'how much cjc-1295 ipamorelin should i take,' and this site does not provide one. No peer-reviewed human trial has ever tested the CJC-1295-plus-ipamorelin combination at any dose for any outcome — the pairing is supported only by separate single-agent pharmacology [3][10]. The community subcutaneous 'stack' regimens circulated online have no controlled human dosing basis and are, by definition, anecdotal rather than evidence-based [3]. What the literature *does* document is single-agent data: ipamorelin's human doses were intravenous and given in a research setting [2], and CJC-1295's human GH and IGF-1 effects came from defined subcutaneous study doses in trials of that drug alone [10]. None of that constitutes a usage instruction. ## How to reconstitute cjc-1295 ipamorelin 5mg On 'how to reconstitute cjc-1295 ipamorelin 5mg': the research-supply literature describes ipamorelin as a lyophilized (freeze-dried) powder, supplied as the free base or acetate salt, that is reconstituted with bacteriostatic water for laboratory handling [2]. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated [2]. These are general peptide-handling observations from the research-supply context, not a clinical preparation instruction and not a dosing protocol — and there is no validated human regimen for a CJC-1295/ipamorelin combination to prepare toward [3]. Any specific concentration or volume someone calculates is a research-handling choice outside the scope of any approved use [3]. --- A bright, plain-English reading of the Ipamorelin record — the clean ghrelin-receptor GH pulse traced to IGF-1 and cited to source, the one failed human trial kept in full view beside the rodent data, and the community reports pinned plainly to one side as anecdote; no clinic behind the page, and nothing here dosed, dispensed, or sold.